HRP20120535T1 - Dihidroksi izopropil fenil morfolin ilmetil fenil izoksazol karboksilna kiselina etilamid mesilat njegovi hidrati i polimorfi te formulacije koje sadrže te oblike - Google Patents

Dihidroksi izopropil fenil morfolin ilmetil fenil izoksazol karboksilna kiselina etilamid mesilat njegovi hidrati i polimorfi te formulacije koje sadrže te oblike Download PDF

Info

Publication number
HRP20120535T1
HRP20120535T1 HRP20120535AT HRP20120535T HRP20120535T1 HR P20120535 T1 HRP20120535 T1 HR P20120535T1 HR P20120535A T HRP20120535A T HR P20120535AT HR P20120535 T HRP20120535 T HR P20120535T HR P20120535 T1 HRP20120535 T1 HR P20120535T1
Authority
HR
Croatia
Prior art keywords
phenyl
morpholin
ylmethyl
dihydroxy
carboxylic acid
Prior art date
Application number
HRP20120535AT
Other languages
English (en)
Croatian (hr)
Inventor
Martin@James@Drysdale
Brian@William@Dymock
Christoph@Krell
Michael@Mutz
Holger@Petersen
Weijia@Zheng
Original Assignee
Novartis@Ag
Vernalis@@R@D@@Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38134307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120535(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis@Ag, Vernalis@@R@D@@Ltd filed Critical Novartis@Ag
Publication of HRP20120535T1 publication Critical patent/HRP20120535T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20120535AT 2007-03-01 2008-02-28 Dihidroksi izopropil fenil morfolin ilmetil fenil izoksazol karboksilna kiselina etilamid mesilat njegovi hidrati i polimorfi te formulacije koje sadrže te oblike HRP20120535T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07103346 2007-03-01
PCT/EP2008/052443 WO2008104595A1 (en) 2007-03-01 2008-02-28 Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms

Publications (1)

Publication Number Publication Date
HRP20120535T1 true HRP20120535T1 (hr) 2012-07-31

Family

ID=38134307

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120535AT HRP20120535T1 (hr) 2007-03-01 2008-02-28 Dihidroksi izopropil fenil morfolin ilmetil fenil izoksazol karboksilna kiselina etilamid mesilat njegovi hidrati i polimorfi te formulacije koje sadrže te oblike

Country Status (40)

Country Link
US (3) US8163747B2 (enExample)
EP (2) EP2131845B1 (enExample)
JP (1) JP2010520176A (enExample)
KR (1) KR20090122218A (enExample)
CN (2) CN102302500A (enExample)
AR (1) AR065519A1 (enExample)
AT (1) ATE552836T1 (enExample)
AU (1) AU2008220800B2 (enExample)
BR (1) BRPI0807992A2 (enExample)
CA (1) CA2678043A1 (enExample)
CL (1) CL2008000618A1 (enExample)
CO (1) CO6210828A2 (enExample)
CR (1) CR10989A (enExample)
CY (1) CY1113805T1 (enExample)
DK (1) DK2131845T3 (enExample)
DO (1) DOP2009000209A (enExample)
EA (1) EA017075B1 (enExample)
EC (1) ECSP099602A (enExample)
ES (1) ES2384906T3 (enExample)
GE (1) GEP20115309B (enExample)
GT (1) GT200900236A (enExample)
HR (1) HRP20120535T1 (enExample)
IL (1) IL200401A0 (enExample)
MA (1) MA31204B1 (enExample)
MX (1) MX2009009233A (enExample)
NI (1) NI200900161A (enExample)
NZ (1) NZ578854A (enExample)
PA (1) PA8771101A1 (enExample)
PE (1) PE20090166A1 (enExample)
PL (1) PL2131845T3 (enExample)
PT (1) PT2131845E (enExample)
RS (1) RS52351B (enExample)
SI (1) SI2131845T1 (enExample)
SM (1) SMAP200900080A (enExample)
TN (1) TN2009000357A1 (enExample)
TW (1) TW200844102A (enExample)
UA (1) UA101950C2 (enExample)
UY (1) UY30943A1 (enExample)
WO (1) WO2008104595A1 (enExample)
ZA (1) ZA200905417B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200922595A (en) * 2007-10-12 2009-06-01 Novartis Ag Organic compounds
TWI450898B (zh) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa 具有抗腫瘤活性之芳基異唑化合物
US8309578B2 (en) 2008-11-25 2012-11-13 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
WO2011089234A2 (en) * 2010-01-21 2011-07-28 Aprea Ab Method and composition
CN102753546A (zh) * 2010-02-17 2012-10-24 日东制药株式会社 新型5-元杂环衍生物及其制备方法
KR20120031854A (ko) 2010-09-27 2012-04-04 한국전자통신연구원 시간 및 주파수 특징을 이용하는 음악 음원 분리 장치 및 방법
WO2013015661A2 (en) * 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101166749B1 (ko) * 2003-02-11 2012-07-27 베르날리스(캠브리지)리미티드 열쇼크 단백질 저해제로서의 이소옥사졸 화합물
US20060070405A1 (en) * 2004-10-06 2006-04-06 Anheuser-Busch, Inc. Method for the production of amber glass with reduced sulfur-containing emissions
CA2677651A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combinations of therapeutic agents for treating cancer
WO2010069458A1 (de) 2008-12-17 2010-06-24 Merck Patent Gmbh Hexahalochromat(lll)-komplexe

Also Published As

Publication number Publication date
ATE552836T1 (de) 2012-04-15
EP2545921A2 (en) 2013-01-16
GT200900236A (es) 2011-09-14
RS52351B (sr) 2012-12-31
TN2009000357A1 (en) 2010-12-31
DK2131845T3 (da) 2012-07-16
EP2545921A3 (en) 2013-04-10
CY1113805T1 (el) 2016-07-27
MA31204B1 (fr) 2010-02-01
EA017075B1 (ru) 2012-09-28
EP2131845B1 (en) 2012-04-11
CO6210828A2 (es) 2010-10-20
KR20090122218A (ko) 2009-11-26
AR065519A1 (es) 2009-06-10
SI2131845T1 (sl) 2013-02-28
CA2678043A1 (en) 2008-09-04
US20130296556A1 (en) 2013-11-07
AU2008220800A1 (en) 2008-09-04
JP2010520176A (ja) 2010-06-10
PL2131845T3 (pl) 2012-09-28
UA101950C2 (ru) 2013-05-27
ES2384906T3 (es) 2012-07-13
TW200844102A (en) 2008-11-16
HK1139073A1 (en) 2010-09-10
NI200900161A (es) 2010-07-27
UY30943A1 (es) 2008-10-31
PT2131845E (pt) 2012-07-10
PE20090166A1 (es) 2009-03-14
US8163747B2 (en) 2012-04-24
EA200901141A1 (ru) 2010-04-30
ECSP099602A (es) 2009-12-28
BRPI0807992A2 (pt) 2014-06-17
NZ578854A (en) 2012-03-30
CN102302500A (zh) 2012-01-04
DOP2009000209A (es) 2009-09-15
MX2009009233A (es) 2010-06-02
GEP20115309B (en) 2011-10-25
CL2008000618A1 (es) 2008-09-12
SMAP200900080A (it) 2010-01-19
PA8771101A1 (es) 2009-02-09
IL200401A0 (en) 2010-04-29
US20120172592A1 (en) 2012-07-05
EP2131845A1 (en) 2009-12-16
US8487095B2 (en) 2013-07-16
US20100093732A1 (en) 2010-04-15
CN101636162A (zh) 2010-01-27
WO2008104595A1 (en) 2008-09-04
ZA200905417B (en) 2010-05-26
AU2008220800B2 (en) 2012-02-16
CR10989A (es) 2010-03-01

Similar Documents

Publication Publication Date Title
RU2008139904A (ru) Фармацевтическая композиция для наружного применения
IL200401A0 (en) Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
PE20121515A1 (es) Acido 2-({3'-cloro-4'-[(2,2-dimetilpirrolidin-1-il)carbonil]-5-fluorobifenil-2-il}oxi)propanoico y sus sales como moduladores del receptor crth2
NZ592224A (en) Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition
NO20073723L (no) Ibandronatpolymorf A
HRP20171572T1 (hr) Tripeptidi kao inhibitori epoksi keton proteaze
NO20080323L (no) Forbindelser og deres salter som er spesifikke overfor PPAR-reseptorer og EGF-reseptorer og deres anvendlse innen medisinen
RU2005138590A (ru) Фармацевтически полезные соли производных карбоновой кислоты
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
MX2020009612A (es) Polimorfos de sal de calcio novedosos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
AR124694A1 (es) Hidrato cristalino de sal de sodio de topramezona novedoso y método de preparación del mismo
MX343611B (es) Composicion de control de fitoenfermedades y su uso.
ATE492159T1 (de) Niedrigschmelzende biocidformulierung
TW200833246A (en) Azolylmethyloxiranes, their use for controlling phytopathogenic fungi, and compositions comprising them
RU2017112971A (ru) Композиции для ухода за полостью рта, содержащие цинк, аргинин и серин
AR073201A1 (es) Compuestos de amida y su uso.
CY1109085T1 (el) Νεα αλατα
PE20120395A1 (es) Sal de potasio cristalina de analogos de lipoxina a4
RU2008151757A (ru) Пероральная композиция, содержащая 3-{5-[4-(циклопентилокси)-2-гидроксибензоил]-2-[(3-гидрокси-1, 2-бензизоксазол-6-ил)метокси]фенил}пропионовую кислоту или ее соль
EA200601963A1 (ru) Соли дигидрожасмоновой кислоты и их применение в сельском хозяйстве
BRPI0507248A (pt) compostos do tipo hidrazina e sua utilização em composições farmacêuticas para o tratamento de doença cardiovasculares
ATE487685T1 (de) (-)-stereoisomer von 2,6-di-sec-butylphenol und analoga davon
JPWO2022264837A5 (enExample)
MX2021014751A (es) Forma cristalina novedosa de derivado de acido 3-(4-(benciloxi)fenil)hex-4-inoico.
PL2096922T3 (pl) Sposób zwalczania chwastów trawiastych za pomocą chwastobójczo skutecznej kompozycji zawierającej jednowartościową sól 4-[2-metylo-3-(4,5-dihydroizoksazol-3-ilo)-4-metylosulfonylo-benzoilo]-1-metylo-5-hydroksy-1H-pirazolu